In this study, we showed that TNF-α-mediated Nav1.6 upregulation was a major factor for RGC hyperexcitability and injury in glaucoma, suggesting that sodium channel blockers selectively targeting on Nav1.6 may be a potential therapeutic strategy in the treatment of glaucoma. The gene discussed is TNF; the disease is glaucoma.